Showing 4551-4560 of 5910 results for "".
- FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Wet AMD and DMEhttps://modernod.com/news/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-wet-amd-and-dme/2480603/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye. Vabysmo is also the first and only FDA-approved inj
- Nanodropper and Lumata Health Launch Partnership Aimed at Improving Patient Carehttps://modernod.com/news/nanodropper-and-lumata-health-launch-partnership-aimed-at-improving-patient-care/2480600/Nanodropper recently announced a partnership with Lumata Health, which includes the launch of a pilot program bringing the Nanodropper Adaptor device to Lumata Health network patients across the United States. Lumata Health is a tech-enabled health care service company fo
- Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseaseshttps://modernod.com/news/kriya-licenses-next-generation-complement-targeted-gene-therapies-for-the-treatment-of-geographic-atrophy-and-other-ocular-diseases/2480593/Kriya Therapeutics announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases. "This partne
- NIH Study Classifies Vision Loss and Retinal Changes in Stargardt Diseasehttps://modernod.com/news/nih-study-classifies-vision-loss-and-retinal-changes-in-stargardt-disease/2480590/National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt. The method quantifies disease-related loss of light-sensing retina cells, yielding information for monitoring patients, understanding genetic causes of the disea
- 2022 President Robert E. Wiggins Jr., MD, MPH Takes the Academy’s Reinshttps://modernod.com/news/2022-president-robert-e-wiggins-jr-md-mph-takes-the-academys-reins/2480585/Medicine is a constantly developing industry—just ask 2022 Academy President Robert E. Wiggins Jr., MD, MPH. When his practice was acquired in the 1990s, Dr. Wiggins returned to school and obtained a masters degree in health care administration, turning Asheville Eye Associa
- Euclid Systems Launches MyEuclid Customer Portalhttps://modernod.com/news/euclid-systems-launches-myeuclid-customer-portal/2480579/Euclid Systems announced an initial launch of MyEuclid, a new interactive, web-based customer portal designed to help drive practice efficiency and optimize Euclid Ortho-K fits. Used on millions of eyes a
- Avellino Enters Into Distribution Agreement With Keeler to Sell Genetic Eye Test AvaGenhttps://modernod.com/news/avellino-enters-into-distribution-agreement-with-keeler-to-sell-genetic-eye-test-avagen/2480576/Avellino Lab USA and Keeler have entered into an agreement where Keeler will distribute AvaGen on its US website. Terms of the deal were not disclosed. AvaGen is the first genetic test that helps determine a patient’s risk of keratoconus and the presence
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Market Scope: Global Refractive Market Rebounds Strongly After COVID-19https://modernod.com/news/market-scope-global-refractive-market-rebounds-strongly-after-covid-19/2480568/The impact of COVID-19 shutdowns initially sharply reduced the number of refractive surgical procedures, but demand has bounced back strongly, with the use of protec
- Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trials for Presbyopia and Dry Eye Diseasehttps://modernod.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/Glaukos announced that it has enrolled the first patient into a phase 2 clinical trial of GLK-302 for the treatment of presbyopia and GLK-301 for the treatment of signs and symptoms of dry eye disease (DED). GLK-302 is the second investigational drug candidate utilizing Glaukos&rsq